Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Body mass index (BMI) greater than or equal to 30.0 kg/m\^2~* New York Heart Association (NYHA) Class II-IV~* Left ventricular ejection fraction (LVEF) greater than or equal to 45% at screening~* Diagnosed with T2D greater than or equal to 90 days prior to the day of screening~* HbA1c of below or equal to 10.0% as measured at the screening visit~Exclusion Criteria:~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 2.4 mg once weekly (OW) (Type: EXPERIMENTAL): Participants will receive semaglutide injections for 52 weeks.
- Semaglutide placebo OW (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide placebo injections for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).